Fact CheckerSign in

NCT07348536Not yet recruiting

Expanded Hemodialysis Versus High-Volume Online Hemodiafiltration for Uremic Toxin Removal

Impact of Expanded Hemodialysis Prescription on Global Uremic Toxin Removal Compared With High-Volume Online Hemodiafiltration: A Randomized Open-Label Crossover Study

Source: ClinicalTrials.gov · Last updated 24 Mar 2026

Brief summary (registry, in English)

People with advanced kidney disease need dialysis to remove waste products from the blood. Some of these waste products, called uremic toxins, are small, while others are medium-sized and more difficult to remove. Poor removal of these toxins may contribute to symptoms and long-term complications in patients on dialysis. Two dialysis techniques are commonly used to improve toxin removal beyond standard hemodialysis: expanded hemodialysis (HDx) using medium cut-off membranes, and high-volume online hemodiafiltration (HV-OL-HDF). Although both techniques are effective, the best way to prescribe expanded hemodialysis-particularly the ideal treatment time-has not been clearly defined. The purpose of this study is to compare how well different treatment times of expanded hemodialysis remove small and medium-sized uremic toxins, and to compare these results with high-volume online hemodiafiltration. Toxin removal will be evaluated using a combined measurement called the Global Removal Score, which summarizes the removal of several important waste substances. This is a single-center, randomized, open-label, crossover study. Adults receiving maintenance hemodialysis will receive three different expanded hemodialysis sessions with different treatment durations (180, 210, and 240 minutes), followed by one session of high-volume online hemodiafiltration. Blood samples will be taken before and after each dialysis session to measure toxin levels. The results of this study may help determine whether expanded hemodialysis with shorter or standard treatment times can achieve toxin removal similar to high-volume hemodiafiltration, which could support more personalized and practical dialysis prescriptions.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
15 (estimated)
First submitted
22 Dec 2025
Start date
Apr 2026
Primary completion date
Apr 2026
Lead sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
NCT number
NCT07348536

What you commit to

  • Study type: Interventional
  • Planned participants: 15
  • From Apr 2026 to the primary completion date, Apr 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Vascular access unable to support a blood flow of at least 300 mL/min

Who the study is looking for

  • Adults aged 18 years or older
  • End stage renal disease Receiving maintenance hemodialysis three times per week on expanded hemodialysis as part of routine care for at least 1 month
  • On dialysis treatment for more than 3 months
  • Minimal or no residual urine output (less than 100 mL per day)
  • Able and willing to provide written informed consent

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Coordinator of this site? Confirm its status
Mexico CityMexicoUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.